Allogeneic stem cell transplantation and targeted immunotherapy for multiple myeloma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue SUPPL. 2, 2013, Pages

  Danylesko, Ivetta ^a   Shimoni, Avichai ^a   Nagler, Arnon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Allogeneic transplantation; Donor lymphocytes infusion; Freedom from progression; Molecular remission; Tandem transplantation

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTHRACYCLINE; BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; THALIDOMIDE; THYMOCYTE ANTIBODY; VINCRISTINE;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CD8+ T LYMPHOCYTE; CHROMOSOME 13; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG MEGADOSE; EVENT FREE SURVIVAL; EX VIVO STUDY; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; KARNOFSKY PERFORMANCE STATUS; LACTATE DEHYDROGENASE BLOOD LEVEL; LONG TERM SURVIVAL; LYMPHOCYTE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; REDUCED INTENSITY CONDITIONING; RELAPSE; REMISSION; SALVAGE THERAPY; T CELL DEPLETION; UNRELATED DONORS; WHOLE BODY RADIATION;

ALLOGENEIC TRANSPLANTATION; DONOR LYMPHOCYTES INFUSION; FREEDOM FROM PROGRESSION; MOLECULAR REMISSION; TANDEM TRANSPLANTATION;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; MULTIPLE MYELOMA; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84889034292     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.05.021     Document Type: Review

References (143)

1. M.S. Raab, K. Podar, and I. Breitkreutz Multiple myeloma Lancet 374 2009 324 339
2. K. Podar, Y.T. Tai, and T. Hideshima Emerging therapies for multiple myeloma Expert Opin Emerg Drugs 14 2009 99 127
3. T.J. McElwain, and R.L. Powles High-dose intravenous melphalan for plasma-cell leukaemia and myeloma Lancet 2 1983 822 824
4. P.J. Selby, T.J. McElwain, and A.C. Nandi Multiple myeloma treated with high dose intravenous melphalan Br J Haematol 66 1987 55 62
5. J.L. Harousseau, and P. Moreau Autologous hematopoietic stem-cell transplantation for multiple myeloma N Engl J Med 360 2009 2645 2654
6. J.A. Child, G.J. Morgan, and F.E. Davies High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 2003 1875 1883
7. J.J. Lahuerta, M.V. Mateos, and J. Martínez-Lopez Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival J Clin Oncol 26 2008 5775 5782
8. B. Paiva, M.B. Vidriales, and G. Mateo The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients Blood 114 2009 4369 4372
9. M. Ladetto, G. Pagliano, and S. Ferrero Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma J Clin Oncol 28 2010 2077 2084
10. W.I. Bensinger Role of autologous and allogeneic stem cell transplantation in myeloma Leukemia 23 2009 442 448
11. P. Corradini, M. Cavo, and H. Lokhorst Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma Blood 102 2003 1927 1929
12. B. Barlogie, R.A. Kyle, and K.C. Anderson Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321 J Clin Oncol 24 2006 929 936
13. B.B. Bjorkstrand, P. Ljungman, and H. Svensson Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation Blood 88 1996 4711 4718
14. W.I. Bensinger, C.D. Buckner, and C. Anasetti Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome Blood 88 1996 2787 2793
15. R. Champlin Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy Br J Haematol 111 2000 18 29
16. C. Crawley, I. Khouri, and A. Shimoni Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning Blood 109 2007 3588 3594
17. G. Tricot, D.H. Vesole, and S. Jagannath Graft-versus-myeloma effect: proof of principle Blood 87 1996 1196 1198
18. P. Corradini, C. Voena, and C. Tarella Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells J Clin Oncol 17 1999 208 215
19. N. Kroger, A. Badbaran, and M. Lioznov Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma Exp Hematol 37 2009 791 798
20. G. Gahrton, S. Tura, and P. Ljungman Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation N Engl J Med 325 1991 1267 1273
21. G. Gahrton, S. Tura, and P. Ljungman Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma J Clin Oncol 13 1995 1312 1322
22. G. Gahrton, H. Svensson, and M. Cava Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres Br J Haematol 113 2001 209 216
23. J. Kuruvilla, J.D. Shepherd, and H.J. Sutherland Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma Biol Blood Marrow Transplant 13 2007 925 931
24. Y. Khaled, S. Mellacheruvu, and P. Reddy Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect Bone Marrow Transplant 44 2009 325 326
25. C. Crawley, M. Lalancette, and R. Szydlo Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT Blood 105 2005 4532 4539
26. S. Giralt, A. Aleman, and A. Anagnostopoulos Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma Bone Marrow Transplant 30 2002 367 373
27. H. Einsele, H. Hebart, and H.J. Schäfer Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning Br J Haematol 121 2003 411 418
28. C.K. Lee, A. Badros, and B. Barlogie Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning Exp Hematol 31 2003 73 80
29. M. Mohty, J.M. Boiron, and G. Damai Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation Bone Marrow Transplant 34 2004 77 84
30. K.S. Peggs, S. Mackinnon, and C.D. Williams Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity Biol Blood Marrow Transplant 9 2003 257 265
31. S. Gerull, M. Goerner, and A. Benner Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma Bone Marrow Transplant 36 2005 963 969
32. B. Bruno, R. Sorasio, and F. Patriarca Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma Eur J Haematol 78 2007 330 337
33. N. Kroger, H.G. Sayer, and R. Schwerdtfeger Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality Blood 100 2002 3919 3924
34. R. Lowsky, T. Takahashi, and Y.P. Liu Protective conditioning for acute graft-versus-host disease N Engl J Med 353 2005 1321 1331
35. W. Bensinger, M. Rotta, and B. Storer Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center Bone Marrow Transplant 47 2012 1312 1317
36. N. Kroger, J.A. Perez-Simon, and H. Myint Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma Biol Blood Marrow Transplant 10 2004 698 708
37. R. Le Blanc, S. Montminy-Métivier, and R. Bélanger Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect Bone Marrow Transplant 28 2001 841 848
38. B. Bruno, M. Rotta, and F. Patriarca Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo Blood 113 2009 3375 3382
39. T. Facon, J.Y. Mary, and C. Hulin Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial Lancet 370 2007 1209 1218
40. B. Bruno, M. Rotta, and F. Patriarca A comparison of allografting with autografting for newly diagnosed myeloma N Engl J Med 356 2007 1110 1120
41. O. Ringden, S. Shrestha, and G.T. da Silva Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma Bone Marrow Transplant 47 2012 831 837
42. V.H. Jimenez-Zepeda, J. Mikhael, and A. Winter Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival Biol Blood Marrow Transplant 18 2012 773 779
43. R.L. Olin, D.T. Vogl, and D.L. Porter Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma Bone Marrow Transplant 43 2009 417 422
44. F. Elice, R. Raimondi, and A. Tosetto Prolonged overall survival with second on-demand autologous transplant in multiple myeloma Am J Hematol 81 2006 426 431
45. R. Fenk, V. Liese, and F. Neubauer Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation Leuk Lymphoma 52 2011 1455 1462
46. C.L. Alvares, F.E. Davies, and C. Horton The role of second autografts in the management of myeloma at first relapse Haematologica 91 2006 141 142
47. M.H. Qazilbash, R. Saliba, and M. De Lima Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma Cancer 106 2006 1084 1089
48. M. Dimopoulos, A. Spencer, and M. Attal Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 2007 2123 2132
49. D.M. Weber, C. Chen, and R. Niesvizky Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl J Med 357 2007 2133 2142
50. P.G. Richardson, P. Sonneveld, and M. Schuster Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial Blood 110 2007 3557 3560
51. P.G. Richardson, P. Sonneveld, and M.W. Schuster Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2005 2487 2498
52. H.Y. Yhim, K. Kim, and J.S. Kim Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT Bone Marrow Transplant 48 2013 425 432
53. S.M. Kazmi, R.M. Saliba, and M. Donato Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma Bone Marrow Transplant 46 2011 510 515
54. P. Zhou, Y. Zhang, and C. Martinez Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination Blood 102 2003 477 479
55. M. Attal, J.L. Harousseau, and T. Facon Single versus double autologous stem-cell transplantation for multiple myeloma N Engl J Med 349 2003 2495 2502
56. M. Cavo, P. Tosi, and E. Zamagni Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study J Clin Oncol 25 2007 2434 2441
57. J. Fermand, K. Desseaux, and J. Marolleau Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: long-term results of a two by two designed randomized trial in 225 young patients with multiple myeloma (MM), for the Group "Myelome-Autogreffe", Caen, Creteil, Limoges, Paris, Strasbourg, France ASH Annual Meeting Abstracts 114 2009 2320
58. H. Goldschmidt Single vs. tandem autologous transplantation in multiple myeloma: the GMMG experience (abstract) Hematol J 4 suppl 1 2003 S61
59. L. Rosinol, R. García-Sanz, and J.J. Lahuerta Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease Haematologica 97 2012 616 621
60. D.G. Maloney, A.J. Molina, and F. Sahebi Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma Blood 102 2003 3447 3454
61. N. Kroger, R. Schwerdtfeger, and M. Kiehl Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma Blood 100 2002 755 760
62. M. Rotta, B.E. Storer, and F. Sahebi Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting Blood 113 2009 3383 3391
63. H.M. Lokhorst, B. van der Holt, and J.J. Cornelissen Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study Blood 119 2012 6219 6225
64. H.M. Lokhorst, B. van der Holt, and S. Zweegman A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma Blood 115 2010 1113 1120
65. G.E. Georges, M.B. Maris, and D.G. Maloney Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma Biol Blood Marrow Transplant 13 2007 423 432
66. H. Avet-Loiseau, X. Leleu, and M. Roussel Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p) J Clin Oncol 28 2010 4630 4634
67. F. Garban, M. Attal, and M. Michallet Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma Blood 107 2006 3474 3480
68. P. Moreau, F. Garban, and M. Attal Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma Blood 112 2008 3914 3915
69. L. Rosinol, J.A. Pérez-Simón, and A. Sureda A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma Blood 112 2008 3591 3593
70. S. Knop, P. Liebisch, and H. Hebart Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment of deletion 13q14 myeloma: an interim analysis of the German DSMM V trial (abstract) Blood 114 2009 51
71. B. Bjorkstrand, S. Iacobelli, and U. Hegenbart Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up J Clin Oncol 29 2011 3016 3022
72. L. Giaccone, B. Storer, and F. Patriarca Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma Blood 117 2011 6721 6727
73. A. Krishnan, M.C. Pasquini, and B. Logan Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial Lancet Oncol 12 2011 1195 1203
74. I. Nivison-Smith, A.J. Dodds, and R. Doocey Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome Leuk Lymphoma 52 2011 1727 1735
75. S.K. Kumar, T.M. Therneau, and M.A. Gertz Clinical course of patients with relapsed multiple myeloma Mayo Clin Proc 79 2004 867 874
76. A. Shimoni, I. Hardan, and F. Ayuk Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up Cancer 116 2010 3621 3630
77. H. de Lavallade, J. El-Cheikh, and C. Faucher Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma Bone Marrow Transplant 41 2008 953 960
78. N. Kroger, A. Shimoni, and G. Schilling Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation Br J Haematol 148 2010 323 331
79. M.C. Minnema, S. van Dorp, and N.W. van de Donk Prognostic factors and outcome in relapsed multiple myeloma after nonmyeloablative allo-SCT: a single center experience Bone Marrow Transplant 46 2011 244 249
80. K. Osman, B. Elliott, and J. Mandeli Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma Am J Hematol 85 2010 249 254
81. Y.A. Efebera, S.R. Qureshi, and S.M. Cole Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma Biol Blood Marrow Transplant 16 2010 1122 1129
82. N. Kroger, T. Zabelina, and E. Klyuchnikov Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients Bone Marrow Transplant 48 2013 403 407
83. N. Kroger, G. Schilling, and H. Einsele Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation Blood 103 2004 4056 4061
84. Q. Bashir, H. Khan, and R.Z. Orlowski Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma Am J Hematol 87 2012 272 276
85. D. Roos-Weil, P. Moreau, and H. Avet-Loiseau Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire Haematologica 96 2011 1504 1511
86. T. Guillaume, D.B. Rubinstein, and M. Symann Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation Blood 92 1998 1471 1490
87. T. Nordoy, A. Husebekk, and I.S. Aaberge Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines Bone Marrow Transplant 28 2001 681 687
88. F.T. Hakim, S.A. Memon, and R. Cepeda Age-dependent incidence, time course, and consequences of thymic renewal in adults J Clin Invest 115 2005 930 939
89. S. Rutella, L. Pierelli, and G. Bonanno Immune reconstitution after autologous peripheral blood progenitor cell transplantation: effect of interleukin-15 on T-cell survival and effector functions Exp Hematol 29 2001 1503 1516
90. M. Lindemann, P. Schuett, and T. Moritz Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and autologous peripheral stem cell transplantation Leukemia 19 2005 490 492
91. A.M. van der Velden, A.M. Claessen, and H. van Velzen-Blad Development of T cell-mediated immunity after autologous stem cell transplantation: prolonged impairment of antigen-stimulated production of gamma-interferon Bone Marrow Transplant 40 2007 261 266
92. L.F. Porrata, M.A. Gertz, and D.J. Inwards Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma Blood 98 2001 579 585
93. H. Ege, M.A. Gertz, and S.N. Markovic Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study Br J Haematol 141 2008 792 798
94. C. Joao, L.F. Porrata, and D.J. Inwards Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma Bone Marrow Transplant 37 2006 865 871
95. L.F. Porrata, D.J. Inwards, and S.M. Ansell Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study Biol Blood Marrow Transplant 14 2008 807 816
96. A.P. Rapoport, N.A. Aqui, and E.A. Stadtmauer Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma Blood 117 2011 788 797
97. L. Li, C. Yee, and J.A. Beavo CD3- and CD28-dependent induction of PDE7 required for T cell activation Science 283 1999 848 851
98. V.A. Boussiotis, G.J. Freeman, and P.A. Taylor p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes Nat Med 6 2000 290 297
99. B.L. Levine, W.B. Bernstein, and M. Connors Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells J Immunol 159 1997 5921 5930
100. J.L. Riley, and C.H. June The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation Blood 105 2005 13 21
101. A.P. Rapoport, E.A. Stadtmauer, and N. Aqui Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer Nat Med 11 2005 1230 1237
102. D. Xu, C. Zheng, and S. Bergenbrant Telomerase activity in plasma cell dyscrasias Br J Cancer 84 2001 621 625
103. K.D. Wu, L.M. Orme, and Jr. Shaughnessy J Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival Blood 101 2003 4982 4989
104. M. Romagnoli, V. Trichet, and C. David Significant impact of survivin on myeloma cell growth Leukemia 21 2007 1070 1078
105. J.F. Rossi, N. Fegueux, and Z.Y. Lu Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects Bone Marrow Transplant 36 2005 771 779
106. M. Steffen, M. Dürken, and U. Pichlmeier Serum interleukin-6 levels during bone marrow transplantation: impact on transplant-related toxicity and engraftment Bone Marrow Transplant 18 1996 301 307
107. M. Condomines, J.L. Veyrune, and M. Larroque Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy J Immunol 184 2010 1079 1084
108. C. Wrzesinski, C.M. Paulos, and L. Gattinoni Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells J Clin Invest 117 2007 492 501
109. M.E. Dudley, J.R. Wunderlich, and P.F. Robbins Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 298 2002 850 854
110. L.X. Wang, S. Shu, and G.E. Plautz Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells Cancer Res 65 2005 9547 9554
111. A. Kobayashi, H. Hara, and M. Ohashi Allogeneic MHC gene transfer enhances an effective antitumor immunity in the early period of autologous hematopoietic stem cell transplantation Clin Cancer Res 13 2007 7469 7479
112. T. Suzuki, S. Ogawa, and K. Tanabe Induction of antitumor immune response by homeostatic proliferation and CD28 signaling J Immunol 180 2008 4596 4605
113. O. Boyman, J.F. Purton, and C.D. Surh Cytokines and T-cell homeostasis Curr Opin Immunol 19 2007 320 326
114. M.M. Sandau, C.J. Winstead, and S.C. Jameson IL-15 is required for sustained lymphopenia-driven proliferation and accumulation of CD8 T cells J Immunol 179 2007 120 125
115. R. Baccala, D. Witherden, and R. Gonzalez-Quintial Gamma delta T cell homeostasis is controlled by IL-7 and IL-15 together with subset-specific factors J Immunol 174 2005 4606 4612
116. M. Burjanadze, M. Condomines, and T. Reme In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma Br J Haematol 139 2007 206 216
117. M. Condomines, P. Quittet, and Z.Y. Lu Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor J Immunol 176 2006 6631 6639
118. C. Choi, M. Witzens, and M. Bucur Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma Blood 105 2005 2132 2134
119. O. Goodyear, K. Piper, and N. Khan CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden Blood 106 2005 4217 4224
120. F. van Rhee, S.M. Szmania, and F. Zhan NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses Blood 105 2005 3939 3944
121. M. Condomines, D. Hose, and P. Raynaud Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis J Immunol 178 2007 3307 3315
122. S. Belle, F. Han, and M. Condomines Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma Eur J Haematol 81 2008 26 35
123. K. Tarte, and B. Klein Dendritic cell-based vaccine: a promising approach for cancer immunotherapy Leukemia 13 1999 653 663
124. G. Martinelli, C. Terragna, and E. Zamagni Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma J Clin Oncol 18 2000 2273 2281
125. S.J. Harrison, and G. Cook Immunotherapy in multiple myeloma-possibility or probability? Br J Haematol 130 2005 344 362
126. N. Kroger, H. Einsele, and D. Wolff Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM) Bone Marrow Transplant 31 2003 973 979
127. H.M. Lokhorst, K. Wu, and L.F. Verdonck The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma Blood 103 2004 4362 4364
128. M. Salama, T. Nevill, and D. Marcellus Donor leukocyte infusions for multiple myeloma Bone Marrow Transplant 26 2000 1179 1184
129. F. Ayuk, A. Shimoni, and A. Nagler Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma Leukemia 18 2004 659 662
130. N. Kroger, W. Krüger, and H. Renges Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma Br J Haematol 112 2001 421 423
131. N. Kroger, A. Shimoni, and M. Zagrivnaja Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma Blood 104 2004 3361 3363
132. D. Chang, N. Liu, and V. Klimek Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications Blood 108 2006 618 621
133. I. Danylesko, K. Beider, and A. Shimoni Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions Clin Dev Immunol 2012 2012 753407
134. N. Kroger, B. Shaw, and S. Iacobelli Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma Br J Haematol 129 2005 631 643
135. C. Wolschke, T. Stübig, and U. Hegenbart Post-allograft lenalidomide induces strong NK cell-mediated anti-myeloma activity and risk for T cell-mediated GvHD. Results from a phase I/II dose-finding study Exp Hematol 41 2013 134 142.e3
136. E. Kneppers, B. van der Holt, and M.J. Kersten Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial Blood 118 2011 2413 2419
137. L.W. Kwak, R. Pennington, and D.L. Longo Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts Blood 87 1996 3053 3060
138. S.S. Neelapu, N.C. Munshi, and S. Jagannath Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma Bone Marrow Transplant 36 2005 315 323
139. S.B. Kim, S. Baskar, and L.W. Kwak In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells Leuk Lymphoma 44 2003 1201 1208
140. B. Barlogie, G. Tricot, and E. Anaissie Thalidomide and hematopoietic-cell transplantation for multiple myeloma N Engl J Med 354 2006 1021 1030
141. A. Shimoni, I. Hardan, and N. Shem-Tov Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan Leukemia 21 2007 2109 2116
142. G. Schilling, T. Hansen, and A. Shimoni Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma Leukemia 22 2008 1250 1255
143. J. El-Cheikh, M. Michallet, and A. Nagler High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma Haematologica 93 2008 455 458